Kronos Bio, Inc. Stock Price, News & Analysis

Kronos Bio (Nasdaq: KRON) announced the appointment of Taiyin Yang, Ph.D., to its board of directors. Dr. Yang brings over 40 years of experience in pharma development, including significant roles at Gilead Sciences, where she led the creation of innovative treatments. Her expertise is expected to aid Kronos in advancing its clinical pipeline. Additionally, Jakob Loven will not seek re-election at the 2021 Annual Meeting. This change comes during a critical growth phase for Kronos, focused on cancer therapies like entospletinib and KB-0742.

Kronos Bio reported significant developments and financial results for 2020. They achieved an End-of-Phase 2 meeting with the FDA for entospletinib, targeting NPM1-mutated acute myeloid leukemia, and initiated a Phase 1/2 trial for KB-0742, a CDK9 inhibitor. The company ended 2020 with $462.1 million in cash and equivalents. For Q4 2020, R&D expenses totaled $13.1 million, with a net loss of $33.2 million ($0.70 per share). The company aims for a Phase 3 trial launch mid-2021, anticipating MRD negative CR data by late 2023.

Kronos Bio, Inc. (Nasdaq: KRON) has announced the presentation of pre-clinical data for KB-0742, a selective CDK9 inhibitor aimed at treating MYC-amplified solid tumors, at the AACR Annual Meeting 2021 from April 10-15. The study indicates that MYC genomic amplification may affect tumor sensitivity to CDK9 inhibition. A Phase 1/2 clinical trial for KB-0742 began earlier this year, with initial safety and pharmacokinetic data expected in Q4 2021, and expansion cohort data anticipated in 2022.

Kronos Bio announced its Phase 3 trial to assess measurable residual disease (MRD) negative complete response (CR) as the primary endpoint for potential accelerated FDA approval of entospletinib in newly diagnosed NPM1-mutated acute myeloid leukemia (AML). The trial is set to begin in mid-2021, with data expected in late 2023. This trial is notable as it marks the first use of MRD as a primary endpoint in AML, aimed at addressing the high mortality rate of this aggressive cancer. MRD negativity is linked to prolonged remissions and improved survival rates.

Kronos Bio has initiated a Phase 1/2 clinical trial for KB-0742, a selective CDK9 inhibitor targeting MYC-amplified solid tumors. The trial, involving 100 patients, aims to assess safety and pharmacokinetics, with initial data expected in Q4 2021. MYC-amplified tumors comprise approximately 30% of solid tumors, presenting a significant treatment opportunity. KB-0742, developed from Kronos' microarray platform, leverages its oral bioavailability and selectivity for CDK9, aiming to advance cancer treatment.

Kronos Bio, Inc. (Nasdaq: KRON) announced its participation in the Cowen 41^st Annual Health Care Conference, set for March 1-4, 2021. The company's CEO, Norbert Bischofberger, Ph.D., will contribute to a panel on "Novel Oncology Targets" on March 1 at 1:20 p.m. ET. Additionally, investor meetings are scheduled for March 2 and 3. Kronos Bio focuses on developing therapies targeting dysregulated transcription factors, with lead drug entospletinib aimed at NPM1-mutated acute myeloid leukemia, and KB-0742 for MYC-amplified solid tumors.

Kronos Bio, Inc. (Nasdaq: KRON) announced the appointment of Marianne De Backer, Ph.D., to its board of directors, bringing over 20 years of healthcare industry experience. Rebecka Belldegrun, M.D., has resigned to pursue other opportunities. Dr. De Backer's extensive background includes leadership at Bayer AG and Johnson & Johnson, where she managed over 200 strategic alliances. She will contribute to the board's compensation committee as Kronos Bio approaches clinical testing for two investigational therapies targeting cancer treatment.

Kronos Bio, Inc. (Nasdaq: KRON) has appointed Pasit Phiasivongsa, Ph.D., as senior vice president of pharmaceutical development. With over 20 years in the biopharmaceutical field, he is expected to enhance the company's manufacturing processes as they prepare for clinical tests of KB-0742 and entospletinib. Dr. Phiasivongsa has a rich background in overseeing CMC strategies and has held significant roles in various companies. His appointment comes at a crucial time as Kronos Bio embarks on important clinical trials targeting cancer therapies.

Kronos Bio, Inc. (Nasdaq: KRON) has received FDA clearance for its Investigational New Drug (IND) application for KB-0742, an inhibitor targeting cyclin dependent kinase 9 (CDK9), aimed at treating MYC-amplified solid tumors. A Phase 1/2 clinical trial is set to commence in Q1 2021, assessing safety and pharmacokinetics. Approximately 30% of solid tumors exhibit MYC amplification, which is a key driver of cancer. Initial data from the trial is expected later in 2021, highlighting the company's commitment to developing innovative cancer therapies.